This Week’s Biopharma News: Big Moves in Bispecifics - Takeaways - MDSpire

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min

Share

  • 1

    Ivonescimab, a PD-1/VEGF bispecific antibody, improved overall survival in advanced squamous NSCLC compared to PD-1 plus chemotherapy.

  • 2

    The phase 3 HARMONi-6 trial showed a 34% reduced risk of death with ivonescimab, achieving median overall survival of 27.9 months.

  • 3

    Amgen's Imdylltra received EU approval as a monotherapy for extensive-stage small cell lung cancer, showing a 40% reduced risk of death.

  • 4

    Renaissance Pharma's anti-GD2 mAb, Daretabart, targets high-risk neuroblastoma and has shown promising survival rates in pediatric patients.

  • 5

    Pfizer and Innovent Biologics entered a $10.5 billion oncology collaboration to develop 12 early-stage programs, retaining rights in Greater China.

Original Source(s)

This Week’s Biopharma News: Big Moves in Bispecifics

  • June 9, 2026

Related Content

STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer

What starts at UCI Health can help shape the national conversation.

  • June 30, 2026

  • 1 min
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min
2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min